Company Oasmia Pharmaceutical AB NORDIC GROWTH MARKET
Equities
OASM
SE0000722365
Pharmaceuticals
Business Summary
Sales per region
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
European Union
100.0
%
| - | - | 1 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-22 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 20-11-30 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-28 |
Johanna Röstin
LAW | General Counsel | 57 | 21-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 19-03-18 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 19-09-25 |
Pål Ryfors
BRD | Director/Board Member | 41 | 22-05-24 |
Roger Tell
BRD | Director/Board Member | 59 | 22-05-24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 538,043,000 | 329,854,634 ( 61.31 %) | 0 | 61.31 % |
Company contact information
![address Oasmia Pharmaceutical AB(OASM)](https://cdn.zonebourse.com/static/address/6758404.png)
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |